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University School of Medicine, Mainz, GermanyObjective. To evaluate the performance of sequential composite bypasses with second generation glutaraldehyde stabilized
human umbilical vein (HUV) and autologous vein.
Design. Retrospective study of consecutive patients, in a single centre.
Patients. From January 1998 to December 2003, 54 femoro-distal HUV-autologous vein sequential composite bypasses
were constructed in 52 patients with critical leg ischemia and absence of sufficient length of autologous vein.
Methods. All infra-inguinal bypass operations were registered in a computerized database and prospectively followed.
Bypasses using sequential HUV-composite technique were reviewed for graft patency, limb salvage and patient survival.
Results. Primary patency and secondary patency rates at 1, 2, 3 and 4 years were 71, 61, 53 and 53% and 89, 80, 73 and
67%, respectively. Corresponding limb salvage rates were 96, 92, 88 and 88%. Patient survival was 56% at 4 years. After 30
days additional procedures to maintain graft patency were necessary in six bypasses. Asymptomatic occlusion of one
sequential anastomosis was found in five patients.
Conclusion. Graft patency and limb salvage rate support the use of the sequential composite technique with second
generation HUV in femorodistal bypass surgery, when autologous vein of sufficient length is not available.Keywords: Limb salvage; Blood vessel prosthesis; Human umbilical vein prosthesis; Bypass; Ischemia.Introduction
Surgery for chronic critical lower limb ischemia using
autologous vein as bypass graft provides favourable
long-term results for limb salvage and bypass
patency.1,2 Results with synthetic prosthetic conduits
for femorodistal bypass are compromised by a high
failure rate, despite additional use of special anasto-
motic techniques.3–5 As an alternative to small calibre
synthetic vascular prostheses, second generation
glutaraldehyde stabilized human umbilical vein
(HUV) has been available for infrainguinal arterial
reconstruction for almost two decades.6 Promising
results regarding patency and limb salvage with the
use of HUV and additional distal AV-fistula for limb
salvage have been reported.7 Others recommend the
sequential bypass technique when autologous vein ising author. Dr A. Neufang, MD, Department of
ic and Vascular Surgery, Johannes Gutenberg Univer-
of Medicine, Langenbeckstrasse 1, 55131 Mainz,
: neufang@mail.uni-mainz.de
0176 + 08 $35.00/0 q 2005 Elsevier Ltd. All rights reserlimited, using a synthetic prosthetic conduit for inflow
anastomosed to the popliteal artery combined with a
suitable vein segment connected to a more distal
artery.8,9 Sequential composite technique using second
generation HUV was employed in patients with
critical leg ischemia and limited availability of auto-
logous vein, in order to optimise prosthetic bypass
run-off. The results of a consecutive single centre series
are presented.Patients and Methods
From a total number of 1231 infrainguinal bypass
operations performed between January 1998 and
December 2003 and prospectively documented in a
computerized database all femoro-distal sequential
HUV-composite bypasses were identified. Patient
characteristics, peri-operative and follow-up data
were obtained retrospectively from patient charts.Eur J Vasc Endovasc Surg 30, 176–183 (2005)
doi:10.1016/j.ejvs.2005.04.026, available online at http://www.sciencedirect.com onved.
Human Umbilical Vein Composite Sequential Bypass 177The work was conducted within the guidelines of the
Ethical Review Board of Rheinland–Pfalz.
Pre-operative duplex scan of the superficial veins of
the ischemic leg and alternative sources, if the
ipsilateral greater saphenous vein had been used
previously, was used whenever possible. Intra-oper-
ative exposure and harvesting of these veins was
followed by assessment of vein quality. Veins of small
calibre or those having inflammatory changes were
excluded. When sufficient autogenous vein, including
spliced vein segments, was available the composite
technique was not used. In order to optimise distal
outflow when the length of autologous vein was
limited and additional prosthetic material was
needed, sequential composite technique was chosen
when more than one arterial segment was assessed as
suitable for distal anastomosis by the operating
surgeon (A.N., W.S.). The HUV-graft was used as
prosthetic inflow part of the sequential composite
bypass. In the presence of a patent popliteal artery
segment combined with occlusion of the proximal
crural arteries and restoration of a more distal patent
crural or pedal artery the proximal sequential anasto-
mosis was performed to the popliteal artery segment.
In all other cases distal anastomoses were located at
patent crural or pedal arteries. HUV bypasses to pre-
existing preserved vein graft bridges of partially
occluded previous sequential vein graft bypasses
were excluded. Composite grafts were constructed
using a single or spliced segment of autologous vein
(greater or lesser saphenous vein, arm vein or
superficial femoral vein) either creating an end-to-
end anastomosis between the HUV and the distal vein
segment anastomosed to two distal arteries (Fig. 1) or
the HUV was anastomosed in end-to-side technique to
a distal vein-graft bridge between two recipient
arteries, according to the technique described by
Deutsch (Fig. 2(A) and (B)).10
Surgery was performed under systemic heparinisa-
tion using conventional anastomotic technique. Graft
patency was confirmed by intra-operative transit time
flow measurement (Cardio-Med Medi-Stim, Oslo,
Norway; Transonic Systems, Ithaca, NY, USA) and
additional post-operative angiography and/or duplex
scan routinely were performed before discharge. Oral
anticoagulation with phenprocumon (Marcumarw)
was started post-operatively using additional continu-
ous intravenous administration of heparin and tem-
porary administration of antiplatelet therapy in all
patients. When a satisfactory INR was reached heparin
and antiplatelet therapy were discontinued.
Follow-up examinations were performed after 3, 6,
12, 18 and 24 months and annually thereafter using
clinical assessment of patency and limb function andduplex-scan. Angiography during follow-up was used
to confirm pathological duplex scan results or if
ischemia of the operated or contra-lateral leg had
developed. A bypass was assessed as patent according
to standard criteria for lower extremity ischemia.11 All
follow-up data prospectively were entered in a
computerized data base (ACCESS 2000 for windows)
and analysed using Kaplan–Meier life-table analysis
and t-test (SPSS 11.0 for windows).Results
From January 1998 to December 2003, 54 femoro-distal
HUV-composite bypasses were performed in 29 men
and 23 women (52 patients) with a mean age of 72G8
years. The median follow-up period was 24 months
(1–69 months). One patient underwent subsequent
bilateral operation and in another patient one limb
required further surgery using the same technique,
after the first sequential composite HUV bypass had
failed. Two bypasses were constructed with three
distal sequential anastomoses to a patent popliteal
artery segment and crural or pedal vessels. Mean
operative time was 265 min (185–387 min). All oper-
ations were performed for critical leg ischemia. Twelve
legs (22%) were operated on for rest pain and 42 legs
(78%) for non-healing ulceration or tissue necrosis. In
all cases, the dissected ipsilateral vein or alternative
veins were not suitable for an autogenous graft of
sufficient length. The proximal HUV graft anastomosis
was located at the common femoral artery or the
proximal superficial femoral artery. Patient character-
istics, risk factors, and operative details are listed in
Tables 1–3.
Intra-operative bypass flow was 190G83 ml/min in
the sequential grafts including a popliteal artery
segment (nZ23) and 177G92 ml/min in grafts
anastomosed to crural and pedal arteries (nZ29) in
the HUV and 58G47 and 63G43 ml/min, respectively,
at the most distal anastomosis, revealing no significant
difference (t-test, pZ0.96 for complete bypass and
pZ0.67 for the level of the distal anastomosis).Early results
One patient died peri-operatively and severe systemic
complications were noted in 11 patients leading to a
combined mortality and morbidity of 20.3% (Table 4).
Early post-operative complete or partial thrombotic
occlusion of the HUV or autologous vein graft was
noted in 13 bypasses (eight complete, five partial)
(24%). Patency could be restored in 11 bypasses byEur J Vasc Endovasc Surg Vol 30, August 2005
Fig. 1. Sequential HUV-composite bypass with segment of
ipsilateral greater saphenous vein.
Table 1. Patient demographics
No. of patients nZ
52
%
Mean age 72.0G8.0 years
(53.8–88.3 years)
Female 23 44
Male* 29 56
Risk factors
Hypertension 45 86
Hyperlipidemia 39 75
Diabetes 42 81
Smoking 18 35
ESRD 7 13
CAD 41 79
Failed surgical revascularisation 12 23
Previous PTA 11 21
Previous inflow procedure 4 8
CAD, coronary artery disease; ESRD, end stage renal disease.
* One patient with bilateral operation.
Table 2. Location and combination of distal anastomoses and
configuration of bypasses
1st Distal anastomosis n 2nd Distal anastomosis n
Popliteal and crural level combined nZ24 (44%), bridge graft nZ10
ak Popliteal 4 Peroneal 2
Anterior tibial 1
Posterior tibial 1
bk Popliteal 20 Peroneal 6*
Anterior tibial 6
Posterior tibial above
ankle
2*
Posterior tibial below
ankle
3
Dorsalis pedis 5
Crural and pedal level combined nZ30 (56%), bridge graft nZ8
Posterior tibial above
ankle
10 Peroneal 4
Dorsalis pedis 3
Posterior tibial below
ankle
1
Plantar 2
Peroneal 17 Posterior tibial above
ankle
5
Posterior tibial below
ankle
6
Plantar 2
Anterior tibial 2
Dorsalis pedis 2
Anterior tibial 2 Dorsalis pedis 1
Posterior tibial above
ankle
1
Posterior tibial below
ankle
1 Dorsalis pedis 1
* In two instances additional anastomoses to the posterior tibial
and the peroneal artery (this explains the number of 22, 2nd distal
anastomoses in 20 bypasses combining the below knee popliteal
artery and crural/pedal arteries).
A. Neufang et al.178means of graft thrombectomy (nZ8; three times in one
case), anastomotic revision (nZ1), partial vein graft
replacement (nZ4) or additional use of an AV-fistula
(nZ1). Revision after post-operative bypass occlusion
was not performed in one limb, in favour of above
knee amputation due to septic forefoot necrosis.
Revision of a thrombosed anastomosis to the medial
plantar artery with patency of a more proximal crural
anastomosis in one patient was not undertaken due toEur J Vasc Endovasc Surg Vol 30, August 2005excessive calcification of the anastomosed plantar
artery and adequate foot perfusion. Additional
minor amputations were necessary in 16 patients.
Infection of a patent HUV-graft was diagnosed in one
case but remained untreated due to a fatal disabling
stroke 6 weeks post-operatively.
Fig. 2. (A) Sequential HUV-composite bypass with short bridge graft. (B) Sequential HUV-composite bypass with long bridge
graft.
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All patients were followed up, with necessary
information obtained during routine surveillance
of the bypass. In cases of severe deterioration of
the patients general health status or death during
follow-up, information regarding the status of the
operated limb was obtained from the attending
general practitioner. Seventeen patients died during
follow-up from cardiovascular events or tumor, 10of whom had a patent graft and 15 of whom had a
viable limb.
Long-term oral anticoagulation was initiated after
48 procedures. In three cases, due to severe post-
operative complications, anticoagulation was not
started and in three patients with severe co-morbid-
ities only antiplatelet therapy was started. Three
patients (6.5%) receiving coumadin therapy experi-
enced bleeding complications during follow-up. In 10
patients (21%), oral anticoagulation was stoppedEur J Vasc Endovasc Surg Vol 30, August 2005
Table 3. Bypass configuration and vein graft material
n %
Proximal bypass (HUV) nZ54
Diameter 5 mm 32 59
Diameter 6 mm 22 41
Conventional sequential bypass
technique
36 66
Bridge graft technique 18 34
Distal sequential bypass (venous part)*
Ipsilateral greater saphenous vein 48 70.6
Contralateral greater saphenous
vein
3 4.4
Lesser saphenous vein 4 5.9
Arm vein 11 16.2
Superficial femoral vein 2 2.9
* A total number of 68 vein segments was used in 54 composite
bypasses. Spliced vein grafts consisting of two or more segments
were used in 14 bypasses.
A. Neufang et al.180during follow-up by the attending general practitioner
for either medical reasons or poor compliance. In four
cases, where oral anticoagulation was not replaced
with other forms of antithrombotic therapy, complete
bypass thrombosis occurred leading to amputation
(nZ2) or re-operation (nZ1). In six patients only
antiplatelet therapy was continued. Three of these
bypasses occluded but without further intervention.
Among the 38 patients maintained on coumadin only
two bypass occlusions were noted, leading to re-
operation in one case. All together late occlusion of the
bypass was noted in 10 instances, including one
sequential re-do bypass necessitating secondary inter-
vention by thrombectomy (two patients) and new
bypass (two patients) (Table 5).
Major amputation was necessary in three patients
with bypass graft thrombosis after discontinuation of
coumadin therapy for medical reasons. Partial distal
bypass occlusion with unimpaired foot perfusion was
found in five patients (Fig. 3). Isolated occlusion of the
inflow HUV graft with a patent distal vein graft bridgeTable 4. Early post-operative (30 days) complications
No. of operations nZ54 n %
Death (MI) 1 1.8
Cardiac failure, arrhythmia 4 7.4
Stroke 3 5.5
Pneumonia/respiratory failure 3 5.5
Deep vein thrombosis 1 1.8
Others 4 7.4
Combined mortality and morbidity
(16 complications in 11 patients)
11 20.3
Graft occlusion complete 8 14.8
Graft occlusion partial 5 9.2
Operative revision performed (successful) 11
(10)
Major amputation 1 1.8
Graft infection 1 1.8
Hematoma 3 5.5
Wound infection/delayed wound healing 8 14.8
Eur J Vasc Endovasc Surg Vol 30, August 2005was found in one patient treated with unsuccessful
lysis and thrombectomy of the HUV but preservation
of the vein bridge with a viable limb. Duplex
surveillance during follow-up identified one severe
stenosis at the proximal anastomosis and two stenoses
of a composite anastomosis necessitating additional
patch angioplasties after 6, 17, 28 and 46 months post-
operatively. Primary and secondary patency were 53
and 67% after 4 years with a limb salvage rate of 88%
using life table analysis (Fig. 4). Aneurysm formation
or other complications related to possible biodegrada-
tion of the HUV were not noted in this series.Discussion
Although the initial reports about the use of glutar-
aldehyde denaturated HUV in infrainguinal recon-
structions indicated promising results with respect to
graft patency, evidence for possible aneurysmal
degeneration led to a massive reduction in the use of
this graft in the first decade after its clinical introduc-
tion.12–15 With this negative experience regarding the
biological behaviour of the first generation HUV graft
a synthetic, small caliber PTFE-graft is preferred by
most vascular surgeons in the absence of a suitable
autologous vein. Despite this clinical practice random-
ised studies have reported superior patency rates for
HUV compared to PTFE grafts in femoro-popliteal
bypass, combined with a low clinical complication rate
of late formation of graft aneurysms.16–19 Results for
below knee femoro-popliteal or tibial bypasses using
PTFE compared to vein still provide significantly
inferior patency and acceptable limb salvage rates,Fig. 3. Asymptomatic occlusion of the second sequential
anastomosis in a bridge graft 15 months post-operatively.
Table 5. Late post-operative (O30 days) complications
Mean follow-up 24 months (1–69 months) No. of operations nZ54 (no. of patients nZ52) %
Death (cardiovascular, tumor) 17 32.6
Late graft occlusion 10 18.5
No revision 6
Amputation 2
Conservative management 4
Thrombectomy (successful) 2 (1)
New bypass 2
Major amputation 3 5.5
Additional operative interventions 5
Patch angioplasty (anastomosis) 2
Patch angioplasty (composite anastomosis) 2
Vein graft extension 1
Human Umbilical Vein Composite Sequential Bypass 181even when additional anastomotic techniques like
vein cuffs or vein patches are employed.3,20,21 Results
of PTFE used without such anastomotic techniques
provide even worse patency and limb salvage and
seem only suitable for patients with limited life
expectancy.22
Reduced blood flow into an impaired outflow tract
with a significant thrombotic potential of the inner
surface of the synthetic prosthesis appears to be one of
the critical issues in femorocrural surgery with
synthetic grafts. Hence, the use of an additional
arterio-venous fistula may be advocated in order to
maximize flow through the graft. Although individual
series from highly experienced surgeons indicate good
long-term results this technique, the use of an
arterio-venous fistula remains controversial.4,23–25
Only Dardik has reported a significant improvementFig. 4. Primary patency, secondary patency and limb salvage
in 54 sequential HUV-composite grafts using the life table
analysis (bypass grafts and limbs left for follow-up at begin
of interval are listed below the curves).using this technique with the HUV graft, with a
promising late patency of 47% at 6 years for femoro-
crural bypasses.26
To optimise synthetic graft outflow others have
emphasized the use of a sequential bypass technique
(in the absence of sufficient length of greater saphe-
nous vein) by either constructing a bypass with a
synthetic graft to a patent popliteal artery segment,
combining it with a distal vein graft extension to a
crural or pedal artery or by the use of a distal
sequential vein anastomosis to the recipient
arteries.27–30 Since 1990 there have been seven studies
with more than 25 cases, describing different sequen-
tial techniques all using PTFE for inflow. In four series
a popliteal artery segment was used in each case.
Deutsch introduced the concept of an inter-crural vein
graft bridge anastomosed to a proximal PTFE graft
and reported promising early results, focusing on
bypasses to infrapopliteal arteries.10 Alexander
reported on 35 bypasses using the sequential compo-
site bypass technique with PTFE as inflow graft and
found a 2-year primary patency of 35% with a limb
salvage rate of 60%.29 Recent studies by Mahmood and
Roddy offer very promising patency rates at 1 and 2
years, between 68 and 80%, and a limb salvage rate of
75 and 88%.8,31 Three and four-year primary patency
rates between 26 and 48% with limb salvage rates
between 30 and 70% were reported by McCarthy,
Oppat and Deutsch using PTFE as inflow grafts.10,28,30
Our results with a 4-year primary patency rate of 53%
and a limb salvage rate of 88% seem to compare
favourably with these previously reported results. The
inclusion of popliteal artery segments in our series
might be questioned but comparison of mean flow in
the HUV graft did not demonstrate significant
differences in the flow distribution in the two groups.
This technique seems to optimise the outflow through
a prosthetic graft without the possible disadvantage of
an AV-fistula, which deviates substantial flow into the
venous circulation.Eur J Vasc Endovasc Surg Vol 30, August 2005
A. Neufang et al.182Although in a randomised trial, oral anticoagula-
tion showed an advantage only for infra-inguinal vein
grafts regarding patency and limb salvage, we treated
our patients with long-term oral anticoagulation
wherever possible, since the distal part of the bypass
consisted of vein.32 The low late occlusion rate of
bypasses maintained on anticoagulation, in combi-
nation with an acceptable rate of bleeding compli-
cations, justifies this treatment. Our reported
technique combines the advantages of a distal vein
graft anastomosis to small calibre arteries combined
with the satisfactory performance of the HUV graft
regarding late graft function. The combination of
residual saphenous vein segments or other alternative
veins with the HUV graft allows conventional tech-
niques for the distal anastomosis. Although the
reported sequential techniques are associated with
additional operative time, theoretically this method
optimises flow to the distal arterial bed, even in
difficult situations with compromised outflow.
The patency rate of our series of 54 bypasses
provides favourable early results using the HUV-com-
posite sequential graft and long-term oral anticoagula-
tion in patients with critical ischemia. Complications
related to bio-degeneration of the HUV grafts were not
identified, although follow-up is still limited.
Although the long-term biological behaviour of
second generation HUV-grafts still has to be
evaluated, it seems to be of minor clinical relevance
in this subgroup of patients with critical ischemia or
those with limited life expectancy.Conclusion
Although there are no randomised trials available
concerning the use of second generation HUV grafts in
femoro-distal bypass surgery, reported historical
results in above knee bypass surgery and the patency
rate in our non-randomised single centre series clearly
support the use of sequential composite bypasses with
second generation HUV, in the absence of suitable
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